Fibrosing alveolitis in systemic sclerosis: The need for early screening and treatment

Internal Medicine Journal

Volumn 34, Issue 11, 2004, Pages 626-638

  Sahhar, Joanne ^a   Littlejohn, G ^a   Conron, M ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Fibrosing alveolitis; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE ANTIBODY; INTERLEUKIN 8; MESNA; METHOTREXATE; PENICILLAMINE; PENTETATE TECHNETIUM TC 99M; PLACEBO; PREDNISOLONE; SCL 70 ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALGORITHM; ALOPECIA; BLADDER CANCER; BLADDER DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; DISEASE MARKER; DOSE RESPONSE; EARLY DIAGNOSIS; FEVER; FIBROSING ALVEOLITIS; HEMATURIA; HEMORRHAGIC CYSTITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; KIDNEY DISEASE; LEUKOPENIA; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG SCINTISCANNING; MAXIMUM PERMISSIBLE DOSE; MYELODYSPLASIA; NAUSEA; NEPHROTOXICITY; OSTEOPOROSIS; PATHOLOGY; PATIENT MONITORING; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SCREENING; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; VOMITING;

BRONCHOALVEOLAR LAVAGE FLUID; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; MASS SCREENING; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 9744228676     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00674.x     Document Type: Review

References (73)

1. Owens GR, Fino GJ, Herbert D, Steen V, Medsger T Jr, Pennock B et al. Pulmonary function in progressive systemic sclerosis; a comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983; 84: 546-50.
2. Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med 1989; 320: 1333-40.
3. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcomes of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352-7.
4. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515.
5. Schneider PD, Wise RA, Hochberg MD, Wigley FM. Serial pulmonary function in systemic sclerosis. Am J Med 1982; 73: 385-94.
6. Peters-Golden M, Wise RA, Schneider P, Hochberg M, Stevens WB, Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine 1984; 63: 221-3.
7. Greenwald GI, Tashkin RP, Gong H, Simmons M, Duann H, Furst D et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis - a prospective study. Am J Med 1987; 83: 83-91.
8. Abramson MJ, Barnett AJ, Littlejohn GO, Smith MM, Hall S. Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger? Postgrad Med J 1991; 67: 632-7.
9. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement Am J Respir Crit Care Med 2000; 161: 646-64.
10. Steen VD, Medsger TA Jr Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
11. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003; 62: 146-150.
12. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9.
13. Wigley FM, Klippel JH, Dieppe PA. Rheumatology, 2nd edn. London: Mosby International; 1998; 7-9.3.
14. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A lifetable analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369-76.
15. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-6.
16. Kim DS, Yoo B, Lee JS, Kim EK, Lim CM, Lee SD et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vase Diffuse Lung Dis 2002; 19: 121-7.
17. Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM et al. Fibrosing alveolitis in systemic sclerosis: Indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-36.
18. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765-70.
19. Harrison NK, Glanville AR, Strickland B, Haslam PL, Corrin B, Addis BJ et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section computed tomography scan, bronchoalveolar lavage and 99m DTPA clearance. Respir Med 1989; 83: 403-14.
20. Chan TYK, Hansell DM, Rubens MB, du Bois RM, Wells AU. Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomography scans. Thorax 1997; 52: 265-70.
21. Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47: 738-42.
22. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G et al. Bronchoalveolar lavage for the evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154: 400-6.
23. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
24. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis C. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18: 455-61.
25. Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheum 1991; 18: 1520-28.
26. Wells AU, Hansell DM, Rubens MB, Cullinan P, Haslam PL, Black CM et al. Fibrosing alveolitis in systemic sclerosis: bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 1994; 150: 462-8.
27. Wells AU, Hansell DM, Harrison NK, Lawrence R, Black CM, du Bois RM. Clearance of inhaled 99mTc DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J 1993; 6: 797-802.
28. Fanti S, De Fabritiis A, Sloisi D. Early pulmonary involvement in systemic sclerosis assessed by technetium 99m DTPA clearance rate. J Nucl Med 1994; 35: 1933-6.
29. Kon OM, Daniil Z, Black CM, du Bois RM. Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J 1999; 13: 133-6.
30. Baron M, Feiglin D, Hyland R, Urowitz MB, Shiff B. Gallium lung scans in progressive systemic sclerosis. Arthritis Rheum 1983; 26: 969.
31. Richard M, Darrin C, Earle L, Varga J. Abnormal uptake of Tc-99m MIBI, a novel myocardial imaging agent in the lungs of patients with systemic sclerosis. Clin Nucl Med 1998; 23: 19-25.
32. Wallaert B, Matron P-I, Grosbois J-M, Tonnel A-B, Devulder B, Voisin C. Subclinical pulmonary involvement in collagen vascular disease assessed by bronchoalveolar lavage - relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis 1986; 133: 574-80.
33. Silver RM, Miller KS, Kinnsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470-76.
34. Win C, Borges AC, John M, Fietze I, Baumann G, Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999; 58: 635-40.
35. Turner-Warwick M, Haslam PL. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135: 26-34.
36. Hunninghake GW, Zimmerman MB, Schwartz DA, King TE Jr, Lynch J, Regele R et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164: 193-6.
37. Raghu G, Mageto YN, Lockart D, Schmidt RA, Wood DE, Goodwin JD et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999; 116: 1168-74.
38. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum TNF alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997; 24: 663-5.
39. Sato S, Nagaoka T, Hasegawa M, Tamatani T, Nakanishi T, Takigawa M et al. Serum levels of connective tissue growth factor (CTGF) are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27: 149-54.
40. Bolster MB, Ludwicka A, Sutherland S, Strange C, Silver R. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997; 40: 743-5.
41. Takahashi H, Kuroki Y, Tanaka H, Saiyo T, Kurokawa K, Chiba H et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000; 162: 258-63.
42. Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000; 200: 196-201.
43. Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000; 27: 930-34.
44. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone and cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-88.
45. Baughman R, Lower E. Use of intermittent intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102: 1090-94.
46. Dayton CS, Schwartz DA, Helmers RA, Peuringa RJ, Gilbert SR, Merchant RK et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies. Chest 1993; 103: 69-73.
47. Collard RH, King TE. Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. Am J Med 2001; 110: 326-8.
48. Flaherty KR, Toews GB, Lynch JP 3rd, Kazerooni EA, Gross BH, Strawderman RL et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110: 278-82.
49. Zisman DA, Lynch JP, Toews GB. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000; 117: 1619-26.
50. Harrison NK, Wells AU, Hansell DM. Treatment of lung disease in systemic sclerosis - a clinical comparison of responders and non-responders. Am Rev Respir Dis 1992; 145: 755A.
51. Steen VD, Conte C, Medsger TA Jr. Case control study of corticosteroid and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-19.
52. Clements PJ, Furst DE, Wong W-K, Mayes M, White B, Wigley F et al. High dose versus low dose D-penicillamine in early diffuse systemic sclerosis. Analysis of a 2 year double-blind randomised, controlled clinical trial. Arthritis Rheum 1999; 42: 1194-203.
53. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low dose prednisolone in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-44.
54. Akkesson A, Scheja A, Anders L, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729-35.
55. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-96.
56. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25: 1325-9.
57. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-6.
58. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298-304.
59. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41: 1215-20.
60. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methyl prednisolone and cyclophosphamide to assess the effect on high resolution computed tomographic scan and lung function. J Rheumatol 2002; 29: 237-8.
61. Winterbauer RH, Hammar SP, Hallman KO, Hays JE, Pardee NE, Morgan EH et al. Diffuse interstitial pneumonitis: clinicopathologic correlations in 20 patients treated with prednisolone/azathioprine. Am J Med 1978; 656: 661-72.
62. Raghu G, De Paso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF et al. Azathioprine combined with prednisolone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-6.
63. Fukazawa M, Kawano M, Hisano S, Ueda K, Matsuba K. Efficacy of cyclosporin A for idiopathic pulmonary fibrosis. Eur J Pediatr 1990; 149: 441-2.
64. Furst DE, Clements PJ, Hillis S, Lachenbach PA, Miller BL, Sterz MG et al. Immunosuppression with chlorambucil versus placebo for scleroderma: results of a 3 year parallel randomized, double blind study. Arthritis Rheum 1989; 32: 584-93.
65. Seibold JR, Korn JH, Simms R. Recombinant human relaxin in the treatment of scleroderma. A randomised double-blind placebo controlled trial. Ann Intern Med 2000; 132: 871.
66. Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002; 19: 1124-7.
67. Kubo M, Vensak J, Dauber J, Keenan R, Griffith B, McCurry K. Lung transplantation in patients with scleroderma. J Heart Lung Transplant 2001; 20: 174-5.
68. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C et al. Phase I/II trial of autologous stem cell transplant in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-84.
69. Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45: 346-54.
70. Ing AJ. Interstitial lung disease and gastroesophageal reflux. Am J Med 2001; 111 (Suppl 8A): 41S-44S.
71. Anon. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-6.
72. Anon. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391-8.
73. Dorr R, VonHoff D, Dorr R, VonHoff D. Cancer Chemotherapy Handbook, 2nd edn. Norwalk, CT: Appleton Lange; 1994; 85-6.